GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Price-to-Operating-Cash-Flow

Biosyent (Biosyent) Price-to-Operating-Cash-Flow : 20.06 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent Price-to-Operating-Cash-Flow?

As of today (2024-04-27), Biosyent's share price is $6.28. Biosyent's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.31. Hence, Biosyent's Price-to-Operating-Cash-Flow Ratio for today is 20.06.

The historical rank and industry rank for Biosyent's Price-to-Operating-Cash-Flow or its related term are showing as below:

BIOYF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.8   Med: 22   Max: 80.7
Current: 20.46

During the past 13 years, Biosyent's highest Price-to-Operating-Cash-Flow Ratio was 80.70. The lowest was 9.80. And the median was 22.00.

BIOYF's Price-to-Operating-Cash-Flow is ranked worse than
57.33% of 675 companies
in the Drug Manufacturers industry
Industry Median: 17.14 vs BIOYF: 20.46

Biosyent's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.31.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biosyent was 5.10% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -7.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 9.00% per year.

During the past 13 years, Biosyent's highest 3-Year average Operating Cash Flow per Share Growth Rate was 267.60% per year. The lowest was -60.70% per year. And the median was 26.70% per year.


Biosyent Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Biosyent's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Price-to-Operating-Cash-Flow Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.30 15.01 22.75 17.72 22.22

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.72 23.66 17.06 14.59 22.22

Competitive Comparison of Biosyent's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biosyent's Price-to-Operating-Cash-Flow falls into.



Biosyent Price-to-Operating-Cash-Flow Calculation

Biosyent's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=6.28/0.313
=20.06

Biosyent's Share Price of today is $6.28.
Biosyent's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Biosyent Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biosyent's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022